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Myocardial infarction (MI) causes loss ofmyocardial tissue leading to
mortality, morbidity and impairment of ventricular function [1]. The
most effective therapy for acute ST-elevation myocardial infarction
(STEMI) is early reperfusion by primary percutaneous coronary
intervention (pPCI) [2]. Reperfusion limitsmyocardial ischemicnecrosis,
but simultaneously accelerates apoptosis by inducing inﬂammation,
oxidative stress, rapid pH normalization, and calcium overload. This
process is called reperfusion injury [3]. Over the last decades, several
therapies have been studiedwith regard to their cardioprotective effects
during reperfusion, including Glucagon-like peptide-1 (GLP-1) [3]. GLP-
1 is an incretin hormone, which lowers blood glucose in a glucose-
dependent manner by stimulating insulin production and secretion in
response to nutrient intake. The GLP-1 receptor is also present in the
heart, and promotes glucose uptake in the myocardium upon stimula-
tion, thereby improving metabolic efﬁciency in the ischemic and
reperfused myocardium [4,5]. Moreover, GLP-1 activates anti-
apoptotic pathways involved in reperfusion injury [6]. GLP-1 is rapidly
degraded by the enzyme dipeptidyl-peptidase-4 (DPP-4) in vivo, which
limits its clinical potential. Exenatide is a long-acting GLP-1 receptor
agonist, and is as such used as a glucose-lowering agent in type 2
diabetes mellitus [7].
Recently, Lonborg et al. demonstrated that adjuvant treatment with a
relatively low intravenous dose of exenatide for 6 h in patients with
STEMI undergoing pPCI improves myocardial salvage [8]. High dose
exenatide might yield a larger cardioprotective effect. However, safety
and feasibility of more intensive exenatide treatment in STEMI patients
remained uninvestigated thus far.
In a randomised placebo controlled study, we assessed the safety and
feasibility of administering high-dose exenatide in patients with a ﬁrst
STEMI undergoing pPCI. The complete outline of this trial has been
described extensively in a prior publication [9]. Patients without
previously known diabetes, aged between 18 and 80 years and able to
undergo pPCI within 6 h after onset of symptoms were asked for
participation. After obtaining informed consent, each patient was
randomised to exenatide or placebo. Just prior to the coronary
angiogram (CAG), a loading dose of 5 μg exenatide or placebo was
administered intravenously in 30 min, followed by a continuous infusion
of 20 μg/24 h for the duration of 72 h. Patients with multivessel disease,
Thrombolysis In Myocardial Infarction (TIMI) 3 ﬂow prior to PCI or
without a deﬁnite culprit lesion were excluded after CAG.
The primary endpoint of this study was safety and feasibility.
Therefore, notorious side-effects as nausea and hypoglycaemia were
closely monitored. Patients visited the outpatient clinic 6 weeks and
4 months after pPCI for recording of clinical events and major adverse
cardiac events (MACE, deﬁned as cardiac death, myocardial infarction,
coronary artery bypass graft surgery or repeat PCI). For identiﬁcation of
abnormal glucose regulation at 4 months, an oral glucose tolerance test
(OGTT) was performed. Secondary endpoints included ﬁnal infarct size
at 4 months as a percentage of the area at risk (AAR) and left ventricular
function measured with cardiovascular magnetic resonance (CMR).
Statistical analysis was performed with SPSS 15.0 (SPSS Inc., Chicago,
Illinois, USA). All data were analysed in a blinded fashion and are
presented as mean with standard errors or median with interquartile
ranges, depending on the data distribution. Student t test or a Mann–
Whitney U test were used appropriately for continuous outcomes and a
Fisher exact probability test for categorical variables. A p-valueb0.05was
considered statistically signiﬁcant. The protocol was approved by the
local medical ethics committee and conforms to the ethical guidelines of
the 1975 Declaration of Helsinki. The authors of this manuscript have
certiﬁed that they comply with the principles of ethical publishing in the
International Journal of Cardiology.
Out of seventy-one patients randomised to exenatide or placebo, 39
patients ﬁnalised the full study protocol, including CMR measurements.
There were no signiﬁcant differences in demographics between both
groups (Table 1). Thirty-two patients were excluded after the initial start
of the study medication, mainly due to angiographic exclusion criteria.
Twenty-two patients receiving exenatide and 21 patients receiving
placebo completed the treatment protocol, and were analysed for all
safety and feasibility endpoints (Table 2). Hypo- or hyperglycemic
episodes were equally divided over both groups. All episodes were
asymptomatic in nature, were of short duration, required no additional
treatment, and did not lead to exclusion of patients. Patients in the
exenatide group experienced treatment-emergent nausea more often.
Nausea resolved instantly in either group after administration of anti-
emetics, and did not lead to lowering or discontinuing of study
medication. No MACE was recorded. Abnormal glucose regulation
detected at the OGTT was equally divided over both groups.
No differences were observed between both groups with regard to
left ventricular function, infarct size or AAR as measured with CMR.
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However there was a trend towards a lower infarct size to AAR ratio in
patients with TIMI 0 or 1 ﬂow prior to PCI receiving exenatide (n=12)
compared to patients receiving placebo (n=11) (35±14% vs. 47±17%,
p=0.094).
This study demonstrates that administering high-dose exenatide
intravenously in patients undergoing pPCI is safe and feasible. The study
was not powered for functional endpoints, however, a trend was
observed towards a smaller infarct size as percentage of the area at risk
in patients with TIMI 0 or 1 ﬂow receiving exenatide. Consequently,
larger studies are required to assess the effect of high-dose exenatide on
myocardial salvage, cardiac function and clinical outcome.
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Table 2
Results of side effects and follow-up oral glucose tolerance test of patients included in
the safety analysis.
Exenatide (n=22) Placebo (n=21) P value
Nausea (%) 11 (50) 4 (19) 0.033
Need for anti-emetics (%) 9 (41) 1 (5) 0.005
Hypoglycaemic episode (%) 6 (27) 3 (14) 0.46
Hyperglycaemic episode (%) 2 (9) 5 (24) 0.24
(n=18)a (n=16)a
OGTT (%) 0.55
Normal glucose regulation 5 (28) 6 (38)
Abnormal glucose regulation 12 (67) 7 (44)
Impaired fasting glucose 12 (67) 7 (44)
Impaired glucose tolerance 5 (28) 3 (19)
Diabetes 1 (6) 3 (19)
OGTT=oral glucose tolerance test.
a 3 patients in the exenatide group and 2 patients in the placebo group refused OGTT.
Table 1
Baseline and angiographic characteristics of patients ﬁnalising full protocol.
Exenatide
(n=19)
Placebo
(n=20)
P value
Age (years) 60±10 58±8 0.58
Male (%) 16 (84) 15 (75) 0.70
BMI (kg/m2) 27±4 27±4 0.59
Family history of CAD (%) 11 (58) 11 (55) 0.86
Smokers (current and previous) (%) 12 (63) 11 (55) 0.61
Hypertension (%) 8 (42) 6 (30) 0.43
Hypercholesterolaemia (%) 5 (26) 6 (30) 0.80
Previous CVA (%) 2 (11) 0 (0) 0.23
β-blocker (%) 1 (5) 5 (25) 0.09
Aspirin (%) 1 (5) 5 (25) 0.96
ACE-inhibitor (%) 1 (5) 0 (0) 0.31
Statin (%) 2 (11) 3 (15) 0.69
Clopidogrel (%) 0 (0) 0 (0) n/a
AT II antagonist (%) 2 (11) 0 (0) 0.14
Glucose at admittance (mmol/L) 7.4 (6.8–9.1) 7.9 (6.7–9.8) 0.42
Creatinin (mmol/L) 85.4±20.4 89.4±22.2 0.56
SGOT (U/L) 29.0±8.0 30.4±10.6 0.66
SGPT (U/L) 26.4±10.8 27.2±10.1 0.81
Culprit lesion (%) 0.88
LAD 6 (32) 5 (25)
RCA 10 (53) 11 (55)
Cx 3 (16) 4 (20)
TIMI ﬂow prior to PCI (%) 0.60
0 11 (58) 8 (40)
1 3 (16) 3 (15)
2 4 (21) 6 (30)
3 1 (5) 3 (15)
Stent type (%) 0.87
Bare metal stent 10 (53) 10 (50)
Drug eluting stent 9 (47) 10 (50)
Length of in-hospital stay (days) 6.21±1.48 6.95±2.91 0.32
Mean symptom-to-balloon-time (min) 129 (108–147) 148 (126–201) 0.10
Mean CCU-to-balloon-time (min) 33 (28–53) 45 (32–61) 0.29
Thrombectomy (%) 17 (90) 17 (85) 1.00
Additional GPIIB/IIIa inhibitor (%) 13 (68) 12 (60) 0.58
Values are depicted as mean±standard deviation or median (IQR) or n (%), unless
otherwise indicated. BMI=body mass index; CAD=coronary artery disease;
CVA=cerebro vascular accident; PCI=percutaneous coronary intervention;
LAD=left anterior descending coronary artery; RCA=right coronary artery;
Cx=circumﬂex coronary artery; TIMI=thrombolysis in myocardial infarction;
CCU=coronary care unit; n/a=not applicable.
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